Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 2 - Caught on Camera

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

MarketBeat

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year

MarketBeat

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

White House Says Trump's Drugmaker Deals Could Save U.S. Economy $529 Billion Over 10 Years

The White House said on Tuesday that agreements with major drugmakers could save the U.S. economy $529 billion over the next decade.

International Business Times

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

MarketBeat

How AstraZeneca's 17,000 AI-certified employees are helping it reach a 'stretch goal' of $80 billion in revenue

CFO Aradhana Sarin breaks down the building blocks behind the revenue target and reflects on a strong Q1.

Fortune

FTSE 100 closes lower as drugs firms GSK and AstraZeneca struggle

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Pharmaceutical giant to invest £300m in Britain after UK-US deal

IN FULL

The Independent UK

AstraZeneca to inject £300 million into UK in surprise U-turn

AstraZeneca chief executive Pascal Soriot has thanked the Government ‘for their efforts to improve access for patients’

The Independent UK

AstraZeneca makes surprise U-turn with £300m pharma investment in UK

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer

The Guardian - UK

Shot in the arm for GSK and AstraZeneca from cancer drug sales

The blue chip drug makers saw first quarter earnings beat market expectations.

Evening Standard

Blue chips close lower amid US-Iran stalemate

For the week, the FTSE 100 fell 2.7%, the FTSE 250 also declined 2.7% and the AIM All-Share dipped 1.7%.

Evening Standard

‘My husband had the Covid-19 vaccine – 11 days later he was dead’

Stephen Ward developed a blood clot after a dose of AstraZeneca

The Independent UK

GSK reports promising early results in ovarian and womb cancer drug trial

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

FTSE 100 ends down as oil rises while Iran war remains in deadlock

The FTSE 100 closed down just 4.82 points at 9,967.35.

The Independent UK

‘We were told it was safe’: Inside the legal battle over Covid vaccine deaths in India

IN FOCUS: In a landmark ruling, India’s top court orders a compensation framework for victims of rare but potentially deadly side effects following Covid vaccination. It’s a victory for families – but questions about transparency, consent and trust remain unresolved. Namita Singh reports

The Guardian - UK

Chinese-owned Syngenta to build new £100m bioscience hub in UK

Agrichemical group will open a research centre in Berkshire, in a move hailed by UK government as ‘clear’ vote of confidence

The Guardian - UK

Sir Ronnie Hampel obituary

Chief executive and chairman of ICI in the 1990s who oversaw the creation of the pharmaceutical company Zeneca

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds

The Conversation

COVID vaccination: we now may know why some people developed blood clots

COVID vaccines saved millions of lives, but months into the rollout, a small number of people began developing dangerous blood clots in unusual parts of the body. These only happened after vaccines that used a modified adenovirus to deliver its payload – such as the AstraZeneca vaccine. Why these blood…

The Guardian - UK

Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss

Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise

The Guardian - UK

Hannah Spencer: the Green MP speaking to everyday people’s frustrations

Winner of Gorton and Denton byelection was driven into politics by growing gap between super-rich and the ‘rest of us’

Evening Standard

HSBC reclaims top spot as FTSE 100 hits new high

The FTSE 100 index ended up 1.2% at 10,806.41, a record close.

Evening Standard

AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025

The drug maker’s annual report showed his total pay lifted 6.4% last year after he was awarded nearly £16 million in bonuses and share awards.

The Guardian - UK

AstraZeneca boss Pascal Soriot’s pay rises to £17.7m

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.